Skip to main content
SpringerLink
Log in

COVID-19

Candida makes a lasting impression in COVID-19

  • News & Views
  • Published:

From Nature Immunology

View current issue Submit your manuscript

Severe COVID-19 is marked by excessive inflammation that can persist after infection. The commensal yeast Candida albicans is now implicated in the acute and chronic immunopathology of COVID-19.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: COVID-19 severity and recovery correlate with changes to the gut mycobiome and systemic markers of inflammation.

References

  1. Thaweethai, T. et al. JAMA 329, 1934–1946 (2023).

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Kusakabe, T. Nat. Immunol. https://doi.org/10.1038/s41590-023-01637-4 (2023).

    Article  PubMed  Google Scholar 

  3. Iliev, I. D. & Leonardi, I. Nat. Rev. Immunol. 17, 635–646 (2017).

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Gold, J. A. W. et al. Emerg. Infect. Dis. 29, 1433–1437 (2023).

    Article  PubMed Central  PubMed  Google Scholar 

  5. Kaul, A. et al. Inflamm. Bowel Dis. 18, 1872–1884 (2012).

    Article  PubMed  Google Scholar 

  6. Jukic, A., Bakiri, L., Wagner, E. F., Tilg, H. & Adolph, T. E. Gut 70, 1978–1988 (2021).

    Article  CAS  PubMed  Google Scholar 

  7. Ebinger, J. E. et al. PLoS One 15, e0236240 (2020).

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Shao, T. Y. et al. Cell Host Microbe 25, 404–417.e406 (2019).

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Yeung, F. et al. Cell Host Microbe 27, 809–822.e806 (2020).

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. George, P. M. et al. Sci. Transl. Med. 14, eabo5795 (2022). A.

    Article  CAS  PubMed  Google Scholar 

  11. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. JAMA 326, 499–518 (2021).

    Article  Google Scholar 

  12. Lamers, M. M. et al. Science 369, 50–54 (2020).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA

    Katherine Lagree & Peter Chen

  2. Widjaja Foundation Inflammatory Bowel & Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA

    Katherine Lagree

  3. The Karsh Division of Gastroenterology and Hepatology, Department of Medicine Cedars-Sinai Medical Center, Los Angeles, CA, USA

    Katherine Lagree

  4. Department of Medicine, Women’s Guild Lung Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA

    Peter Chen

Authors
  1. Katherine Lagree
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Chen.

Ethics declarations

Competing interests

The authors have no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lagree, K., Chen, P. Candida makes a lasting impression in COVID-19. Nat Immunol 24, 1782–1784 (2023). https://doi.org/10.1038/s41590-023-01648-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41590-023-01648-1

  • Springer Nature America, Inc.

Search

Navigation